BioLineRx (BLRX) Capital Expenditures (QoQ) (2013 - 2024)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 15.63% |
| Mar 31, 2024 | -100.00% |
| Dec 31, 2023 | -1,500.00% |
| Sep 30, 2023 | 98.51% |
| Jun 30, 2023 | -109.38% |
| Mar 31, 2023 | 43.86% |
| Dec 31, 2022 | -375.00% |
| Sep 30, 2022 | 72.73% |
| Jun 30, 2022 | -144.44% |
| Mar 31, 2022 | 70.97% |
| Dec 31, 2021 | -2,166.67% |
| Sep 30, 2021 | 115.79% |
| Jun 30, 2021 | 0.00% |
| Mar 31, 2021 | -2,000.00% |
| Dec 31, 2019 | -1,200.00% |
| Sep 30, 2019 | 95.45% |
| Jun 30, 2019 | 29.03% |
| Mar 31, 2019 | 68.04% |
| Jun 30, 2018 | 59.26% |
| Mar 31, 2018 | 76.42% |
| Dec 31, 2017 | -1,105.26% |
| Sep 30, 2017 | 57.78% |
| Jun 30, 2017 | 0.00% |
| Mar 31, 2017 | -140.18% |
| Jun 30, 2016 | 80.29% |
| Mar 31, 2016 | 36.87% |
| Dec 31, 2015 | 75.34% |
| Sep 30, 2015 | 38.76% |
| Jun 30, 2015 | -864.43% |
| Mar 31, 2015 | -380.65% |
| Dec 31, 2014 | 54.41% |
| Sep 30, 2014 | -65.85% |
| Jun 30, 2014 | 12.77% |
| Mar 31, 2014 | -56.67% |
| Dec 31, 2013 | -57.89% |
| Sep 30, 2013 | 24.00% |
| Jun 30, 2013 | -127.27% |